-
随着经济发展和医学技术的进步,核医学近年来发展迅速。SPECT全身骨显像是早期诊断恶性肿瘤骨转移的首选方法,在核医学影像检查中的应用最为广泛,在很多医院,该检查方法占核医学影像检查方法的80%以上[1-2]。99Tcm-MDP是全身骨显像常用的放射性药物,其可释放长射程γ射线。全身骨显像受检者服用或者被注射放射性药物后,即成为移动辐射源,因此对非核医学科临床工作人员和患者陪检家属、探视者等受到的辐射剂量安全评估尤其重要[3]。笔者就99Tcm-MDP全身骨显像受检者注射药物后的外照射剂量进行研究,以期对非核医学科人员的辐射防护提供理论依据。
-
受检者静脉注射99Tcm-MDP后0.5 h,对于水平距离腹部不同的距离,排尿组受检者的辐射剂量当量率小于未排尿组,且差异有统计学意义(表1)。
组别 与腹部的水平距离(m) 0.5 1 2 4 6 排尿组(n=39) 40.29±4.67 15.22±1.64 4.15±0.47 1.32±0.10 0.45±0.05 未排尿组(n=12) 77.29±10.71 29.48±4.56 7.45±1.07 2.63±0.31 0.78±0.15 Z值 5.197 5.148 5.251 5.199 5.202 P值 <0.001 <0.001 <0.001 <0.001 <0.001 注:表中所有数据均已扣除本底0.14 μSv/h;MDP:亚甲基二膦酸盐 表 1 2组受检者静脉注射99Tcm-MDP 0.5 h后不同距离的辐射剂量当量率(
,μSv/h)$\bar{x}\pm s$ Table 1. Radiation equivalent dose rate of the two groups of subjects at different distances from the abdomen after intravenous injection of 99Tcm-MDP 0.5 h(
, μSv/h)$\bar{x}\pm s$ -
由表2可知,在排尿组受检者腹部或头部水平距离0.5、1、2、4、6 m处,注射药物0.5、1、2、3、4、6 h后的辐射剂量当量率之间比较,腹部(F=5397.675,P<0.001)和头部(F=4834.512,P<0.001)不同时间之间的差异均有统计学意义;腹部(F=3459.712,P<0.001)和头部(F=3105.426,P<0.001)不同距离之间的差异也均有统计学意义。排尿组受检者的辐射剂量当量率随着药物注射后时间的延长显著下降,在距离腹部水平0.5 m处3 h时下降约38.27%。
测量部位 测量水平距离(m) 测量时间(h) 0.5 1 2 3 4 6 腹部 0.5 40.29±4.67 36.64±3.25 34.58±2.98 24.87±1.91 14.01±0.97 9.68±0.94 1 15.22±1.64 13.10±0.97 12.62±1.10 10.19±1.00 5.24±0.50 3.29±0.22 2 4.15±0.47 3.69±0.36 3.67±0.34 3.64±0.27 1.66±0.13 0.96±0.08 4 1.32±0.10 1.25±0.07 1.07±0.09 1.03±0.10 0.73±0.07 0.51±0.06 6 0.45±0.05 0.46±0.04 0.34±0.04 0.27±0.04 0.20±0.03 0.12±0.02 头部 0.5 41.38±3.86 38.25±3.89 28.49±3.23 20.96±2.63 11.68±1.10 4.33±0.55 1 12.56±1.29 11.79±1.53 11.32±0.98 9.76±0.87 4.75±0.40 2.96±0.30 2 4.21±0.50 3.98±0.47 3.53±0.34 3.42±0.27 1.86±0.17 1.11±0.12 4 1.36±0.14 1.33±0.15 1.15±0.09 0.96±0.12 0.85±0.11 0.54±0.07 6 0.45±0.06 0.42±0.04 0.40±0.05 0.31±0.05 0.23±0.03 0.16±0.04 注:表中所有数据均已扣除本底0.14 μSv/h;MDP:亚甲基二膦酸盐 表 2 39例排尿组受检者99Tcm-MDP全身骨显像后的辐射剂量当量率(
,μSv/h)$\bar{x}\pm s$ Table 2. The radiation equivalent dose rate of the 39 subjects (urination group ) who had undergone 99Tcm-MDP whole body bone imaging (
, μSv/h)$\bar{x}\pm s$ -
与排尿组受检者腹部水平距离0.5 m处6 h的累积剂量当量[(148.51±13.83)μSv(最高为214.58 μSv、最低为117.63 μSv)]相比,1 m处6 h的累积剂量当量[(55.85±5.22)μSv(最高为89.24 μSv、最低为47.15 μSv)]显著下降(下降约62.39%),且差异有统计学意义(Z=5.610,P<0.001)。与排尿组受检者头部水平距离0.5 m处6 h的累积剂量当量[(132.74±12.95) μSv,最高为196.01 μSv]相比,1 m处6 h的累积剂量当量显著下降,且差异有统计学意义(Z=5.438,P<0.001)。在受检者腹部水平距离6 m处,6 h的累积剂量当量为(2.56±0.24)μSv(最高为3.63 μSv、最低为1.97 μSv)。排尿组受检者的累积剂量当量随着照射时间的延长而增加、随着距离的增加而减少,具体数据详见表3。
测量部位 测量水平距离(m) 测量时间(h) 0.5 1 2 3 4 6 腹部 0.5 23.66±2.21 44.27±4.25 77.86±7.55 103.35±9.99 122.69±11.18 148.51±13.83 1 9.00±1.02 16.82±1.59 29.51±2.84 39.08±3.33 46.30±4.41 55.85±5.22a 2 2.62±0.19 4.92±0.37 8.75±0.76 11.72±1.23 14.03±1.35 17.22±1.40 4 0.79±0.06 1.52±0.12 2.82±0.27 3.95±0.32 4.92±4.36 6.47±0.55 6 0.32±0.02 0.61±0.04 1.14±0.10 1.58±0.13 1.96±0.15 2.56±0.24 头部 0.5 26.90±2.45 48.82±4.34 81.22±7.06 102.72±10.10 116.99±10.72 132.74±12.95 1 7.87±0.71 14.74±1.39 25.98±2.03 34.55±3.40 41.09±4.21 49.88±4.72a 2 2.55±0.23 4.83±0.49 8.68±0.76 11.74±1.15 14.19±1.13 17.69±1.66 4 0.81±0.06 1.56±0.11 2.91±0.22 4.08±0.36 5.09±0.42 6.72±0.54 6 0.31±0.02 0.61±0.05 1.14±0.09 1.61±0.13 2.03±0.18 2.71±0.02 注:表中所有数据已扣除本底0.14 μSv/h;a:与受检者水平距离0.5 m处6 h的累积剂量当量比较,差异有统计学意义(Z=5.610、5.438,均P<0.001);MDP:亚甲基二膦酸盐 表 3 39例排尿组受检者99Tcm-MDP全身骨显像后的累积剂量当量(
,μSv)$\bar{x}\pm s $ Table 3. Cumulative equivalent doses of the 39 subjects (urination group ) who had undergone 99Tcm-MDP whole body bone imaging (
, μSv)$\bar{x}\pm s $
99Tcm-MDP全身骨显像受检者外照射剂量的研究
External exposure dose of 99Tcm-MDP from subjects awaiting whole-body bone scan
-
摘要:
目的 研究99Tcm-亚甲基二膦酸盐(MDP)全身骨显像受检者对非核医学科人员的外照射剂量,以有效减少非受检者的受照辐射剂量。 方法 选取 2018年8月至2019年1月在中国科学技术大学附属第一医院行99Tcm-MDP全身骨显像的51例受检者进行回顾性研究,其中男性26例、女性25例,年龄22~91(62.23±13.36)岁。所有受检者注射925 MBq 99Tcm-MDP后,根据饮水1000 mL后0.5 h内有无排尿分为排尿组(n=39)和未排尿组(n=12),检测注射药物后0.5、1、2、3、4、6 h时受检者腹部和头部水平距离0.5、1、2、4、6 m处的辐射剂量当量率和累积剂量当量。2组间比较采用两独立样本的Mann-Whitney U检验,多次测量的不同时间、不同距离辐射剂量当量率的比较采用重复测量方差分析,配对样本采用非参数Wilcoxon检验。 结果 排尿组受检者在腹部水平距离0.5、1、2、4、6 m处的辐射剂量当量率均低于未排尿组[(40.29±4.67)μSv/h对(77.29±10.71)μSv/h、(15.22±1.64)μSv/h对(29.48±4.56)μSv/h、(4.15±0.47)μSv/h对(7.45±1.07)μSv/h、(1.32±0.10)μSv/h对(2.63±0.31)μSv/h、(0.45±0.05)μSv/h对(0.78±0.15)μSv/h],且差异均有统计学意义(Z=5.148~5.251,均P<0.001)。排尿组受检者腹部和头部的辐射剂量当量率均随着时间和距离的增加而迅速降低,且差异有统计学意义(F=3105.426~5397.675,均P<0.001);排尿组受检者的辐射剂量当量率随着药物注射后时间的延长而显著下降。与排尿组受检者腹部水平距离0.5 m处6 h的累积剂量当量[(148.51±13.83)μSv]相比,1 m处6 h的累积剂量当量[(55.85±5.22)μSv]显著下降,且差异有统计学意义(Z=5.610,P<0.001);与排尿组受检者头部水平距离0.5 m处6 h的累积剂量当量[(132.74±12.95)μSv]相比,1 m处6 h的累积剂量当量[(49.88±4.72)μSv]显著下降,且差异有统计学意义(Z=5.438,P<0.001);排尿组受检者的累积剂量当量随着照射时间的延长而增加、随着距离的增加而减少。 结论 99Tcm-MDP全身骨显像对于非核医学科人员的照射剂量远远小于国内、国际法律规定限值(个人年有效剂量当量≤1 mSv),与注射药物后3 h的受检者距离1 m以上即可避免大部分额外辐射。 Abstract:Objective To analyze the radiation-exposure dose of non-nuclear medical staff from patients who had undergone 99Tcm-MDP administration for whole-body bone scan. Methods From August 2018 to January 2019, 51 subjects who had undergone whole-body bone scan in our department were selected. The subjects were injected with 925 MBq 99Tcm-MDP and had drunk 1000 mL of water. They were divided into two groups, namely, micturition and non-micturition groups within 0.5 h. The equivalent dose rates of external radiation 0.5, 1, 2, 4, and 6 m away from the head or abdomen of the subject were measured at 0.5, 1, 2, 3, 4, and 6 h after 99Tcm-MDP injection and water drinking by using an χ, γ dosimeter. The Mann-Whitney U test of two independent samples was used to compare two groups. Repeated-measurement ANOVA was used to compare different times and distances of multiple measurements. The nonparametric Wilcoxon Z test was used for paired samples. Results The radiation equivalent dose rates of 0.5, 1, 2, 4, and 6 m in the urination group were significantly lower than those in the non-urination group [(40.29±4.67) μSv/h vs. (77.29±10.71) μSv/h, (15.22±1.64) μSv/h vs. (29.48±4.56) μSv/h, (4.15±0.47) μSv/h vs. (7.45±1.07) μSv/h, (1.32±0.10) μSv/h vs. (2.63±0.31) μSv/h, (0.45±0.05) μSv/h vs. (0.78±0.15) μSv/h], and the differences were statistically significant (Z=5.197, 5.148, 5.251, 5.199, and 5.202, respectively; all P<0.001). The radiation equivalent dose rates of the abdominal or head level in the urination group decreased rapidly with prolonged time (F=5397.675 and 4834.512, respectively; both P<0.001) and with increased distance (F=3459.712 and 3105.426, respectively; both P<0.001), and the differences were statistically significant. Meanwhile, the cumulative equivalent dose increased with prolonged time and decreased distance. Compared with the 6 h cumulative dose equivalent (148.51±13.83) μSV at 0.5 m of abdominal horizontal distance in urination group, the 6 h cumulative dose equivalent (55.85±5.22) μSV at 1 m of abdominal horizontal distance in urination group decreased significantly (Z=5.610, P<0.001). Compared with the 6 h cumulative dose equivalent (132.74±12.95) μSV at 0.5 m of head horizontal distance in urination group, the 6 h cumulative dose equivalent (49.88±4.72) μSV at 1 m of head horizontal distance in urination group decreased significantly (Z=5.438, P<0.001). The cumulative dose equivalent in urination group increased with the extension of irradiation time and decreased with the increase of distance. Conclusion The external exposure dose of 99Tcm-MDP from patients awaiting whole-body bone scan was far less than the limitation (≤1 mSv/year per individual) set by domestic and international legal rules for non-nuclear medical staff. Most of the exposure risks of non-nuclear medicine staff to 99Tcm-MDP from patients could be avoided by staying more than 1 m from the patient 3 h after injection. -
表 1 2组受检者静脉注射99Tcm-MDP 0.5 h后不同距离的辐射剂量当量率(
,μSv/h)$\bar{x}\pm s$ Table 1. Radiation equivalent dose rate of the two groups of subjects at different distances from the abdomen after intravenous injection of 99Tcm-MDP 0.5 h(
, μSv/h)$\bar{x}\pm s$ 组别 与腹部的水平距离(m) 0.5 1 2 4 6 排尿组(n=39) 40.29±4.67 15.22±1.64 4.15±0.47 1.32±0.10 0.45±0.05 未排尿组(n=12) 77.29±10.71 29.48±4.56 7.45±1.07 2.63±0.31 0.78±0.15 Z值 5.197 5.148 5.251 5.199 5.202 P值 <0.001 <0.001 <0.001 <0.001 <0.001 注:表中所有数据均已扣除本底0.14 μSv/h;MDP:亚甲基二膦酸盐 表 2 39例排尿组受检者99Tcm-MDP全身骨显像后的辐射剂量当量率(
,μSv/h)$\bar{x}\pm s$ Table 2. The radiation equivalent dose rate of the 39 subjects (urination group ) who had undergone 99Tcm-MDP whole body bone imaging (
, μSv/h)$\bar{x}\pm s$ 测量部位 测量水平距离(m) 测量时间(h) 0.5 1 2 3 4 6 腹部 0.5 40.29±4.67 36.64±3.25 34.58±2.98 24.87±1.91 14.01±0.97 9.68±0.94 1 15.22±1.64 13.10±0.97 12.62±1.10 10.19±1.00 5.24±0.50 3.29±0.22 2 4.15±0.47 3.69±0.36 3.67±0.34 3.64±0.27 1.66±0.13 0.96±0.08 4 1.32±0.10 1.25±0.07 1.07±0.09 1.03±0.10 0.73±0.07 0.51±0.06 6 0.45±0.05 0.46±0.04 0.34±0.04 0.27±0.04 0.20±0.03 0.12±0.02 头部 0.5 41.38±3.86 38.25±3.89 28.49±3.23 20.96±2.63 11.68±1.10 4.33±0.55 1 12.56±1.29 11.79±1.53 11.32±0.98 9.76±0.87 4.75±0.40 2.96±0.30 2 4.21±0.50 3.98±0.47 3.53±0.34 3.42±0.27 1.86±0.17 1.11±0.12 4 1.36±0.14 1.33±0.15 1.15±0.09 0.96±0.12 0.85±0.11 0.54±0.07 6 0.45±0.06 0.42±0.04 0.40±0.05 0.31±0.05 0.23±0.03 0.16±0.04 注:表中所有数据均已扣除本底0.14 μSv/h;MDP:亚甲基二膦酸盐 表 3 39例排尿组受检者99Tcm-MDP全身骨显像后的累积剂量当量(
,μSv)$\bar{x}\pm s $ Table 3. Cumulative equivalent doses of the 39 subjects (urination group ) who had undergone 99Tcm-MDP whole body bone imaging (
, μSv)$\bar{x}\pm s $ 测量部位 测量水平距离(m) 测量时间(h) 0.5 1 2 3 4 6 腹部 0.5 23.66±2.21 44.27±4.25 77.86±7.55 103.35±9.99 122.69±11.18 148.51±13.83 1 9.00±1.02 16.82±1.59 29.51±2.84 39.08±3.33 46.30±4.41 55.85±5.22a 2 2.62±0.19 4.92±0.37 8.75±0.76 11.72±1.23 14.03±1.35 17.22±1.40 4 0.79±0.06 1.52±0.12 2.82±0.27 3.95±0.32 4.92±4.36 6.47±0.55 6 0.32±0.02 0.61±0.04 1.14±0.10 1.58±0.13 1.96±0.15 2.56±0.24 头部 0.5 26.90±2.45 48.82±4.34 81.22±7.06 102.72±10.10 116.99±10.72 132.74±12.95 1 7.87±0.71 14.74±1.39 25.98±2.03 34.55±3.40 41.09±4.21 49.88±4.72a 2 2.55±0.23 4.83±0.49 8.68±0.76 11.74±1.15 14.19±1.13 17.69±1.66 4 0.81±0.06 1.56±0.11 2.91±0.22 4.08±0.36 5.09±0.42 6.72±0.54 6 0.31±0.02 0.61±0.05 1.14±0.09 1.61±0.13 2.03±0.18 2.71±0.02 注:表中所有数据已扣除本底0.14 μSv/h;a:与受检者水平距离0.5 m处6 h的累积剂量当量比较,差异有统计学意义(Z=5.610、5.438,均P<0.001);MDP:亚甲基二膦酸盐 -
[1] Fleury V, Ferrer L, Colombié M, et al. Advantages of systematic trunk SPECT/CT to planar bone scan (PBS) in more than 300 patients with breast or prostate cancer[J/OL]. Oncotarget, 2018, 9(60): 31744−31752[2019-12-13]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114966. DOI: 10.18632/oncotarget.25860. [2] 余悦. 99mTc-MDP骨显像患者外照射水平及铅衣的屏蔽效果评价[D]. 长春: 吉林大学, 2016.
Yu Y. External exposure of patients with 99mTc-MDP bone scanning and evaluation of shielding effect about lead protective clothing[D]. Changchun: Jilin University, 2016.[3] 李宁, 肖国有, 郭威, 等. 某医院核医学科环境辐射检测与评价分析[J]. 中国辐射卫生, 2015, 24(4): 358−360. DOI: 10.13491/j.cnki.issn.1004-714x.2015.04.015.
Li N, Xiao GY, Guo W, et al. Analysis of environmental radiation detection and evaluation in the nuclear medicine department of a hospital[J]. Chin J Radiol Health, 2015, 24(4): 358−360. DOI: 10.13491/j.cnki.issn.1004-714x.2015.04.015.[4] 王铁. 核医学影像医师[M]. 北京: 人民卫生出版社, 2016: 272−274.
Wang T. Nuclear medical imaging physician[M]. Beijing: People's Medical Publishing House, 2016: 272−274.[5] 赵海敏. 99mTc-MDP SPECT/CT扫描对骨转移瘤的诊断价值及所致辐射剂量的研究[D]. 济南: 山东大学, 2014.
Zhao HM. Diagnostic value for bone metastasis on 99mTc-MDP SPECT/CT scanning and studies of related radiation dose[D]. Jinan: Shandong University, 2014.[6] Kuji I, Yamane T, Seto A, et al. Skeletal standardized uptake values obtained by quantitative SPECT/CT as an osteoblastic biomarker for the discrimination of active bone metastasis in prostate cancer[J/OL]. Eur J Hybrid Imaging, 2017, 1(1): 2[2019-12-13].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5954671. DOI: 10.1186/s41824-017-0006-y. [7] Banezhad F, Ayati N, Toosi FS, et al. Extraosseous accumulation of Technetium-99m-methyl diphosphonate (99mTc-MDP) in a child with all: a case report[J]. Asia Ocean J Nucl Med Biol, 2018, 6(1): 57−60. DOI: 10.22038/aojnmb.2017.9679. [8] 房迎春. 核医学科99mTc患者剂量及其防护[D]. 抚州: 东华理工大学, 2016.
Fang YC. Dose and protection of 99mTc patients in nuclear medicine[D]. Fuzhou: East China University of Technology, 2016.[9] Partap A, Raghunanan R, White K, et al. Knowledge and practice of radiation safety among health professionals in Trinidad[J]. SAGE Open Medicine, 2019, 7(1): 1−7. DOI: 10.1177/2050312119848240. [10] 郑爱国, 秦景香, 翁玮, 等. 2010-2013年上海市宝山区放射工作人员外照射个人剂量监测分析[J]. 职业卫生与应急救援, 2015, 33(5): 319−321. DOI: 10.16369/j.oher.issn.1007-1326.2015.05.003.
Zheng AG, Qin JX, Weng W, et al. Individual doses of radiation workers in Baoshan district of Shanghai from 2010 to 2013[J]. Occup Health Emerg Rescue, 2015, 33(5): 319−321. DOI: 10.16369/j.oher.issn.1007-1326.2015.05.003.[11] Booth C, Tudor GL, Katz BP, et al. The delayed effects of acute radiation syndrome: evidence of long-term functional changes in the clonogenic cells of the small intestine[J]. Health Phys, 2015, 109(5): 399−413. DOI: 10.1097/HP.0000000000000356. [12] 中华人民共和国质量监督检验检疫总局. GB18871-2002 电离辐射防护与辐射源安全基本标准[S]. 北京: 中国标准出版社, 2002.
General Administration of Quality Supervision Inspection and Quarantine of the People's Republic of China. GB18871-2002 Basic standard for protection against ionizing radiation and safety of radiation sources[S]. Beijing: China Standard Press, 2002.[13] 中华人民共和国卫生部, 中国国家标准化管理委员会. GB16361-2012 临床核医学的患者防护与质量控制规范[S]. 北京: 中国标准出版社, 2012.
Ministry of Health of the People's Republic of China, National Standardization Administration of China. GB16361-2012 Specification for patient radiological protection and quality control in nuclear medicine[S]. Beijing: China Standard Press, 2012.[14] Granlund C, Thilander-Klang A, Ylhan B, et al. Absorbed organ and effective doses from digital intra-oral and panoramic radiography applying the ICRP 103 recommendations for effective dose estimations[J]. Br J Radiol, 2016, 89(1066): 20151052. DOI: 10.1259/bjr.20151052.